JOINN Laboratories (China) Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100004BP3
HKD
21.22
0.3 (1.43%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.98 M

Shareholding (Sep 2025)

FII

0.78%

Held by 1 FIIs

DII

99.22%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Flat results in Dec 24

3

With ROE of 1.32%, it has a Very Expensive valuation with a 0.29 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 2,573 Million ()

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.15%

stock-summary
Debt Equity

-0.29

stock-summary
Return on Equity

0.35%

stock-summary
Price to Book

0.29

Revenue and Profits:
Net Sales:
738 Million
(Quarterly Results - Dec 2025)
Net Profit:
238 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.31%
0%
6.31%
6 Months
-9.7%
0%
-9.7%
1 Year
68.95%
0%
68.95%
2 Years
131.66%
0%
131.66%
3 Years
-30.54%
0%
-30.54%
4 Years
-68.56%
0%
-68.56%
5 Years
-84.73%
0%
-84.73%

JOINN Laboratories (China) Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
11.98%
EBIT Growth (5y)
-184.71%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.29
Tax Ratio
14.46%
Dividend Payout Ratio
30.26%
Pledged Shares
0
Institutional Holding
0.78%
ROCE (avg)
8.78%
ROE (avg)
6.56%

Valuation key factors

Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
0.29
EV to EBIT
102.60
EV to EBITDA
-7.05
EV to Capital Employed
-0.21
EV to Sales
-0.55
PEG Ratio
NA
Dividend Yield
0.15%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
1.32%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.78%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -0.12% vs -13.41% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 52.99% vs 120.54% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "737.90",
          "val2": "738.80",
          "chgp": "-0.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.30",
          "val2": "120.20",
          "chgp": "-113.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.70",
          "chgp": "-42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "305.30",
          "val2": "68.50",
          "chgp": "345.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "238.20",
          "val2": "155.70",
          "chgp": "52.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-85.70%",
          "val2": "107.30%",
          "chgp": "-19.30%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -17.80% vs -16.98% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 327.25% vs -82.53% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,797.30",
          "val2": "2,186.60",
          "chgp": "-17.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "36.70",
          "val2": "236.50",
          "chgp": "-84.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "3.00",
          "chgp": "-40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "393.80",
          "val2": "-137.70",
          "chgp": "385.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "323.00",
          "val2": "75.60",
          "chgp": "327.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-78.30%",
          "val2": "34.70%",
          "chgp": "-11.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
737.90
738.80
-0.12%
Operating Profit (PBDIT) excl Other Income
-16.30
120.20
-113.56%
Interest
0.40
0.70
-42.86%
Exceptional Items
305.30
68.50
345.69%
Consolidate Net Profit
238.20
155.70
52.99%
Operating Profit Margin (Excl OI)
-85.70%
107.30%
-19.30%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -0.12% vs -13.41% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 52.99% vs 120.54% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,797.30
2,186.60
-17.80%
Operating Profit (PBDIT) excl Other Income
36.70
236.50
-84.48%
Interest
1.80
3.00
-40.00%
Exceptional Items
393.80
-137.70
385.98%
Consolidate Net Profit
323.00
75.60
327.25%
Operating Profit Margin (Excl OI)
-78.30%
34.70%
-11.30%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -17.80% vs -16.98% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 327.25% vs -82.53% in Dec 2024

stock-summaryCompany CV
About JOINN Laboratories (China) Co., Ltd. stock-summary
stock-summary
JOINN Laboratories (China) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available